InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Haft Nicholas, Director. Director active across 1 company, notably Finch Therapeutics Group, Inc.. Cumulatively, 2 reports have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €1.2m. Activity tracked since 20 December 2021. The latest transaction was disclosed on 20 December 2021 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations2 total
63,850 shares@ US$10.184.97% mcap50.0% of flowCommon Stock, $0.001 par value per shareSEC:0001567619-21-022453:0
Ideal exit: 16 Sept 2022 (T+270)
63,850 shares@ US$10.18100.0% of flowCommon Stock, $0.001 par value per shareSEC:0001567619-21-022453
Ideal exit: 16 Sept 2022 (T+270)
2 of 2 declarations
About Haft Nicholas
Nicholas Haft is a Director at Finch Therapeutics Group, Inc. In this role, he participates in the governance of the company and strategic decision-making. His expertise in biotechnology is valuable for Finch Therapeutics, which develops innovative therapies.
